Sort   by:  
 Page size 
TranscriptomicsSubtype-specific genomic alterations define new targets for soft tissue sarcoma therapy
This SuperSeries is composed of the following subset Series: GSE21122: Whole-transcript expression data for soft-tissue sarcoma tumors and control normal fat specimens GSE21123: Affymetrix SNP array data for soft tissue sarcoma samples Refer to individual Series
ORGANISM(S): Homo sapiens 
2010-07-05 | E-GEOD-21124 | biostudies-arrayexpress
TranscriptomicsAffymetrix SNP array data for soft tissue sarcoma samples
Soft tissue sarcomas are aggressive mesenchymal cancers that affect more than 10,600 new patients per year in the US, about 40% of whom will die of their disease. Soft tissue sarcomas exhibit remarkable histologic diversity, with more than 50 recognized subtypes, but our knowledge of their genomic a...
ORGANISM(S): Homo sapiens 
2010-07-05 | E-GEOD-21123 | biostudies-arrayexpress
TranscriptomicsAgilent 244K aCGH data for colon cancer samples
Mutation of the gene PARK2 is the most common cause of early-onset Parkinson's Disease (PD)1,2. PARK2 encodes a gene product with E3 ubiquitin ligase activity3. In a search for multisite tumor suppressors, we identified PARK2 as a frequently targeted gene on chromosome 6q25.2-q27 in cancer. Here,...
ORGANISM(S): Homo sapiens 
2010-06-22 | E-GEOD-18638 | biostudies-arrayexpress
UnknownPrevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.
Not available
S-EPMC3753703 | biostudies-literature
TranscriptomicsWhole-transcript expression data for soft-tissue sarcoma tumors and control normal fat specimens
Soft tissue sarcomas are aggressive mesenchymal cancers that affect more than 10,600 new patients per year in the US, about 40% of whom will die of their disease. Soft tissue sarcomas exhibit remarkable histologic diversity, with more than 50 recognized subtypes, but our knowledge of their genomic a...
ORGANISM(S): Homo sapiens 
2010-07-05 | E-GEOD-21122 | biostudies-arrayexpress
UnknownAKT Inhibition in Solid Tumors With AKT1 Mutations.
Not available
S-EPMC5501365 | biostudies-literature
UnknownPhase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Not available
S-EPMC5834157 | biostudies-literature
GenomicsEvolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined. DNA hypermethylation of the O 6 -methylguanine-DNA methyltransferase (MGMT) promoter is associated with an improve...
EGAS00001001179 | EGA
Genomicsena-DATASET-VUMC-CCA-03-09-2014-18:57:30:134-11 - samples
Background: The disease course of patients with diffuse low-grade glioma is notoriously unpredictable. Temporal and spatially distinct samples may provide insight into the evolution of clinically relevant copy number aberrations (CNAs). The purpose of this study is to identify CNAs that are indicati...
EGAD00001001000 | EGA
GenomicsJ_Costello_20150303_dataset - samples
Dataset contains WES data from 3 astrocytoma patients: blood as control, primary tumor and recurrent tumor
EGAD00001001305 | EGA
Sort   by:  
 Page size